Beclometasone dipropionate/formoterol maintenance and reliever therapy asthma exacerbation benefit increases with blood eosinophil level
A number of studies have evaluated the effectiveness of a “Maintenance And Reliever Therapy” (MART) regimen combining in a single inhaler the rapid-acting, long-acting β2-agonist (LABA) formoterol fumarate (FF) with an inhaled corticosteroid (ICS) in asthma. Such a regimen is now established for the treatment of moderate-to-severe asthma in adolescents and adults in many guidelines. Furthermore, rescue short-acting β2-agonists (SABAs) are no longer recommended as sole therapy even for patients with mild asthma, and an ICS/FF combination used as needed is the preferred reliever therapy.
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2021 |
Schlagwörter: | Asthma exacerbation / long-acting β2-agonist (LABA) / short-acting β2-agonists (SABA) / formoterol fumarate (FF) / inhaled corticosteroid (ICS) / maintenance and reliever therapy (MART) |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-28838344 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://hdl.handle.net/11392/2460961 |